Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study.Diabetes Care. 2008; 31: 1582-1584
- Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.Circulation. 2008; 117: 3002-3009
- Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med. 2008; 358: 2545-2559
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med. 2008; 358: 2560-2572
- Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med. 2009; 360: 129-139
- Standards of medical care in diabetes—2011.Diabetes Care. 2011; 34: S11-S61
- High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial.Am J Cardiol. 2000; 86: 19L-22L
- Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction.Diabetes Care. 2007; 30: 479-484
- Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study.Circulation. 2009; 120: 212-220
- Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005.Circulation. 2009; 119: 1728-1735
- High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies.Circulation. 1989; 79: 8-15
- Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.Arch Intern Med. 2009; 169: 1775-1780
- Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.JAMA. 1988; 260: 641-651
- Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med. 2001; 345: 1583-1592
- Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).Circulation. 1998; 97: 1453-1460
- Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.JAMA. 2001; 285: 1585-1591
- Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.Am J Cardiol. 2009; 104: 1689-1694
- Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation. 2004; 110: 227-239
- Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.Circulation. 2008; 117: 2123-2130
- Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study.J Am Coll Cardiol. 2011; 57: 153-159
- Effects of combination lipid therapy in type 2 diabetes mellitus.N Engl J Med. 2010; 362: 1563-1574
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.Lancet. 2005; 366: 1849-1861
This study was funded by Takeda Pharmaceuticals America, Deefield, Illinois. In addition, Dr. Nichols has received research funding from Merck Research Laboratories, Rahway, New Jersey, Novartis Pharmaceuticals, East Hanover, New Jersey, GlaxoSmithKline, Philadelphia, Pennsylvania, and Tethys Bioscience, Emeryville, California.
Dr. Nichols researched the data and wrote the manuscript; Dr. Vupputuri contributed to the discussion and reviewed and edited the manuscript; and A. G. Rosales conducted the statistical analyses and reviewed and edited the manuscript.